Scancell is expected to conclude licensing deals on both of its two cancer vaccine platforms. The shares will rise steeply when the first of these deals is announced. Getting in ahead of these deals while the shares are cheap makes a lot of sense.
Are you kidding me? Because the Sunday Times has just leaked that Scancell's SCIB1 vaccine trials have proved successful. Seems that speculation is turning towards a possible licensing deal or an outright sale of the company. Either option would send these shares into orbit. Super STRONG BUY!r r [link]